![CDATA[ [if IE 9] ]]>
This test is only qualitative and should not be used for routine monitoring (ie, quantitative mRNA level).
Monitoring of most patients with chronic myeloid leukemia (CML) should be performed using BCRAB / BCR/ABL, p210, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Chronic Myelogenous Leukemia (CML), Varies.
Monitoring of patients known to carry a p190 fusion should be performed using BA190 / BCR/ABL, p190, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Quantitative, Monitoring Assay, Varies.
DIAGNOSTIC workup of patients with a high probability of BCR-ABL1-positive hematopoietic neoplasms, predominantly chronic myelogenous leukemia and acute lymphoblastic leukemia.
Refrigerate specimens must arrive within 5 days of collection, and ambient specimens must arrive with 3 days (72 hours) of collection. Collect and package specimens as close to shipping time as possible.
The following information is required:
1. Pertinent clinical history including if the patient has a diagnosis of chronic myelogenous leukemia or other BCR/ABL1-positive neoplasm
2. Date of collection
3. Specimen source (blood or bone marrow)
An interpretive report will be provided.
When positive, the test identifies the specific mRNA fusion variant present to guide selection of an appropriate monitoring assay.
Monitoring is available for common p210 or p190 fusion variant detected.
-Common fusion variants detected: e13-a2 or e14-a2 (p210), e1-a2 (p190), and e6-a2 (p205*)
-Rare fusion variants detected: e13-a3 (p210), e14-a3 (p210), e1-a3 (p190), e19-a2 (p230)
-Potential rare fusions detected: e12-a3, e19-a3
*This is formerly observed as the e6-a2 (p185) fusion form.